The Dr. Hyman Show - Are Psychedelics The Solution To The Opioid Crisis? with Deborah Mash

Episode Date: October 19, 2022

This episode is brought to you by Cozy Earth, InisdeTracker, and Rupa Health. If you or a loved one struggle with addiction, this is an episode you’re going to want to listen to. Many of our current pharmaceuticals stem from compounds discovered in plant medicines. And many beneficial plants that were discovered decades ago still have huge potential for changing modern medicine—ibogaine is one of them. Today on The Doctor’s Farmacy, I’m excited to sit down with Dr. Deborah Mash to discuss the use of the African plant ibogaine and its metabolite, noribogaine, in the treatment of addiction and how it could impact the devastating opioid epidemic.  Dr. Deborah Mash is one of the world's foremost experts on ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical-stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder. DemeRx has partnered with ATAI Life Sciences—a global biotech platform with a special focus on psychedelic medicine—to develop ibogaine for those suffering from opioid use disorder. Building on the extensive human data available around ibogaine, DemeRx and ATAI are conducting a Clinical Phase I/II trial in opioid-dependent patients. This landmark trial will advance screening procedures, dosing guidelines, and best practices for opioid withdrawal management and relapse prevention.   This episode is brought to you by Cozy Earth, InisdeTracker, and Rupa Health. Cozy Earth makes the most comfortable, temperature-regulating, and nontoxic sheets on the market. Right now, get 40% off your Cozy Earth sheets. Just head over to cozyearth.com and use code MARK40. InsideTracker is a personalized health and wellness platform like no other. Right now they’re offering my community 20% off at insidetracker.com/drhyman. Rupa Health is a place where Functional Medicine practitioners can access more than 2,000 specialty lab tests from over 20 labs like DUTCH, Vibrant America, Genova, and Great Plains. You can check out a free, live demo with a Q&A or create an account at RupaHealth.com. Here are more details from our interview (audio version / Apple Subscriber version): The long history of ibogaine’s ethnobotanical and ethnopharmacological use (7:01 / 4:10)  The power of ibogaine to reset opioid tolerance and bypass many withdrawal symptoms in a single dose (15:41 / 8:11)  How ibogaine works (20:59 / 14:15)  Using ibogaine to protect against future relapse (26:09 / 19:25)  Efforts to understand the importance of ibogaine’s psychedelic effects (30:05 / 24:54)  Assessing the success rates of recovery and relapse prevention from ibogaine treatment (37:49 / 34:02)  Understanding the underlying drivers of addiction for better recovery and relapse treatment (41:46 / 37:55)  The concept of “psychoplastogens” and turning on synaptic plasticity in the brain (51:44 / 47:52)  Humanity’s relationship to plants and plant medicines (57:25 /  53:34)  Risks associated with and considerations for seeking ibogaine treatment (1:03:24 / 59:37) Learn more about Dr. Mash’s work at demerx.com.

Coming up on this episode of The Doctor's Pharmacy. Maybe these molecules are so important at a time when society is more difficult, when people are feeling more isolated, things are too fast, we don't get off the grid enough to allow the brain to heal. Hey everyone, it's Dr. Mark. I don't think there's anything better than waking up, feeling super rested, relaxed, and energized. When we get high quality sleep, that's the norm. Without it, our simple day-to-day tasks

can seem impossible and our health suffers. That's why I'm always looking for ways to upgrade my sleep routine, and bamboo sheet sets from Cozy Earth is my new favorite way to get an amazing night's rest. You might be surprised to learn that many types of bedding out there contain toxins that can off-gas into your air and absorb into your skin.

Do you want to sleep on formaldehyde? I don't either. So I know that Cozy Earth's products are certified to be free from harmful chemicals, and that's why I love them. Sleep actually impacts every part of our health. It helps us maintain a healthy weight by balancing hormones and blood sugar, provides time to detox our brains, lets our muscles and organs rest and repair. But so many of us don't get enough sleep or the right quality of sleep to allow the body to do all these important things. Better sleep is the cornerstone of better health and is something we all have the

power to work on. I know nice bedding can feel like a big investment, so Cozy Earth makes it super easy to try out their products with a 30-day free trial and a 10-year warranty. Plus, right now they're offering the best sale price ever with 40% off. Just go to CozyEarth.com, use the code MARK40 at checkout, and that's CozyEarth, C-O-Z-Y-E-A-R-T-H.com with the code MARK40 and check out. And I know you love these sheets as much as I do. You're unique, which means your health and wellness plans should be unique too. But it can be tough to optimize your health and nutrition programs because it's often difficult to get the data you need. And even if you do get your numbers, you actually have to understand them and then be able to

make meaningful action based on them. This is where InsideTrackers comes in. InsideTracker is a wellness tracker that uses science and technology to deliver ultra-personalized healthcare guidance. They can analyze your blood, your DNA, your lifestyle habits, and then give you actionable recommendations to help you meet your health and wellness goals. They'll tell you what you need to do and why, and you can track your progress and adjust your plan based on real-time feedback from your own body. Since 2009, their science team at Harvard, Tufts, and MIT have been bringing

personalized nutrition and wellness to the world with their powerful evidence-based digital platform. InsideTracker is simple, customizable, and most importantly, it's based on you and your body. If you're curious about getting your own health program dialed in to meet your unique needs, I highly recommend checking out InsideTracker. Right now, they're offering my community 20% off at InsideTracker.com forward slash Dr. Hyman. That's I-N-S-I-D-E-T-R-A-C-k-e-r.com slash d-r-h-y-m-a-n and you'll see the discount code in your cart. Welcome to the doctor's pharmacy. I'm Dr. Mark Hyman. That's pharmacy when I have a place for conversations that matter. If you or anyone you know struggle with addiction or mental illness

and are looking for novel solutions, this podcast may be very relevant to you because it's going to be about a compound you may never have heard about that might just hold the key to solving addiction called Ibogaine from the plant Iboga. And it's with one of the world's leading experts on Ibogaine, Dr. Deborah Mash. I met her a number of months ago at a conference and was really blown away by the level of research and focus that she's had over the last decades, I should say, to explore the power of this compound to heal one of the worst problems of humanity, which is addiction. She's the co-founder and the founder and CEO of Demorex, which is a clinical

stage drug development company advancing Ibogaine and its active metabolite called Noribogaine for the treatment of opioid use disorder. They partnered with Atai Life Sciences, which is a global biotech platform that's focusing on psychedelic medicine to develop Ibogaine for those who suffer from opioid use disorder. And building on extensive human data available around Ibogaine, they are conducting a clinical phase one to trial now in opioid-dependent patients. This really is a landmark trial that's going to advance screening procedures, dosing guidelines, and best practices for opioid withdrawal management and preventing relapse. She is the Merit Professor of Neurology

and Pharmacology at the University of Miami School of Medicine, has published over 300 articles and monographs in the fields of neuroscience, pharmacology, and the neurobiology of addiction. Welcome, Debra, to The Doctor's Pharmacy. Thank you. Okay, well, let's get into it. This is a big problem we have, not just opioid addiction, but addictions of all kinds, alcohol, food addiction, gambling addiction, workaholism. I certainly suffer from that. I don't know if that would be curable by Ibogaine, but maybe. And we are now suffering with a staggering opioid epidemic.

We all have heard about it. You know, there's over 100,000 people who died last year, up from 75,000 from opioid overdose. Often it starts with a legitimate pain prescription for pills that can be helpful, but then gets out of control. There are 4 million people in America who are addicted to pain meds and heroin. A growing number are overdosing from a surge in these fentanyl spike pills that are on the open drug market out there. It's really a devastating and debilitating disease for so many people, for so many families. And it's just, it's made worse by the fact that recover rates really for addiction using standard approaches and rehab-based options

don't work that well. I mean, it's a little bit, but not that great. And I mean, drugs like methadone and suboxone can help, but, but we're really not very far ahead in the last, you know, 70, 80 years on addiction. Now you, you've been studying this compound, uh, from a plant from a West African tree, the bark of a shrub, I think, native to West Central Africa called iboga. And you told a story at this conference that I went to, which sort of heralded the discovery of this as an addiction treatment medicine. Because for years it's been used, and centuries maybe, it's been used as a ritual drug and rites of initiation and passage and

you know that are from a spiritual tradition but but there was a discovery uh over 30 years ago in amsterdam and then you continued on in miami and caribbean to actually look at this compound as being able to disrupt addiction specifically for for opioids. So can you talk about that discovery? Tell us the original story and then give us a sort of an overview of this last decades of your exploration of this. And then we'll get into sort of the nitty gritty of what's going on with this research that you're doing and the importance of this drug and this compound. Ibogaine has a very long history of ethnobotanical and ethnopharmacologic use. And in fact, it goes over a hundred years because remember, prior to the development

of novel pharmaceuticals, which really, you know, came about in the, in the 1950s, most blockbuster drugs came from Mother Nature. So there was a real push, primarily by the Europeans, but also Americans and others to look to nature for finding pharmaceutical drug candidates to be advanced for treatments of a variety of illnesses from everything from infective diseases. And of course, the CNS division is a little bit more complicated. But Ibogaine is an indole alkaloid. So what does that mean? Mother Nature gives us addicting alkaloids. Addicting alkaloids are like nicotine, cocaine, opium,

things that humans will take to get high come from come from nature and so here's this molecule from western equatorial africa that's used in low doses for stimulating behavior mild stimulant effect by the local by local people who explored, again, Mother Nature, but then in high doses found its way into ethno-Christian religious practices in Africa, and that these were by the Bwiti religion. So Ibogaine, like other psychedelic medicines, is a sacrament, a plant sacrament, or what we call a plant teacher. So this is the interesting, you know, legend and lore that goes back over 100 years. But when the pharmaceutical drug hunters were in Africa and other parts of the world, Asia, etc., they brought back Ibogaine, and Ibogaine was really advanced in France, and it made its way in low-dose tablets into the French pharmacies.

So many of the original pharmacies in France were able to make tinctures and potions and pills in their own shop. And Ibogaine was marketed under the trade name Lamberine until the early 1970s. So people took it for its antidepressant effects. And what we know today is that when you take a low dose of Ibogaine, it is converted to the Ibogaine active metabolite or nor Ibogaine. So that experiment was done, actually, for us for 20 years in France. In the 60s, when people became interested in LSD and psilocybin and the so-called hallucinogens and the DEA began to clamp down on these classes of drugs, there was a seminal discovery by a man named Howard Letzoff. He died several years ago, but he is credited with this discovery. And Howard was, you know, like many other people exploring, you know, molecules for consciousness,

expansion, himself was a heroin addict. And he had been abusing opioids for many years. And he took a dose of Ibogaine to experience the drug. There were groups out in California who had access to Ibogaine. It's a difficult, actually, molecule to get. It's not like mushrooms, which you can just grow and you can find them. Ibogaine is a little more complicated for one to access. But he was involved in this underground movement and he was a filmmaker, young filmmaker, et cetera. He takes the dose of Ibogaine and discovers that he's detoxified

off opiates. He completely abruptly stops taking opiates, has no cravings or desire to use the drug, go back out and get high to treat withdrawals, and he has no desire to use. So this was the original discovery. And when was that, Deborah? That was in the early 70s. In the early 70s, in the early 70s, when LSD was making its way from academic universities, from Harvard and elsewhere and became that whole movement. Ibogaine had made its way into the US and diplomatic pouch and underground therapists in California were working with it and some people in New York. So he has this experience, repeats the experience with six of his friends. Some were addicted to

opiates. Some were abusing cocaine, hard-core cocaine abusers, using freebase and cocaine. And they too had similar experiences. With that observation, it was a number of years, and Howard Lotsoff and a group around him, his entourage forms a company called NDA International. And they started an underground railroad of addicts helping addicts. These were people, and this is what they called it, the addict self-help movement. And so people from the United States and from Amsterdam, the International Coalition of Addict Self-Help and the Dutch Add self-help movement started to run this underground railroad where people could go outside of Amsterdam and take

Ibogaine. I leave Boston. I did my fellowship at Beth Israel hospital and at Harvard and then joined the faculty at the university in Miami, right at the, at the peak of the cocaine epidemic in South Florida. So we were, you know, we were Miami Vice. Cocaine was making its way through the Caribbean into Miami, and we were hit front-end loading of the cocaine epidemic. I had been working on Alzheimer's disease and got pulled into this by my colleagues who were at the medical examiner's office, because young people were dying from cocaine related deaths. And they were dying with what we thought at the time was rather low doses of cocaine in their blood. So people didn't really know what was going on. And then there were some adverse psychiatric effects. We had crack exposed

infants, it was a mess, increases in crime, you know the story. And I had been credited, my laboratory did work on coca-ethylene, and your listeners may know what that is or not, but when you drink and use cocaine in combination, your liver transesterifies, and so you've got an extra drug on board. You've got coca, the ethyl homolog or coca ethylene. We disclose this, describe it. It's more reinforcing. It takes off the edge of the cocaine. And unfortunately, it's more lethal. So we disclose this, get national recognition. And in the course of getting a lot of media attention for the work, we were called the Miami Vice Metabolite. I started to hear about this drug from Africa. And it happened three times. I heard it three times. I was at a coalition for a drug-free

America giving a lecture about my research and a gentleman, an African-American man came up to me at the podium and said, Dr. Mash, have you heard about this drug from Africa? And he's going on and on. And I think I was short with him and abrupt because I'd never heard of it. And I didn't know what he was talking about. Second time I heard about it was Stan Glick, a professor from Albany University was working with these drug taking rats. You know, rats will self-administer at high rates of responding everything that humans will abuse. So they'll drink alcohol, they'll take nicotine, cocaine, other psychostimulants and opiates. So he gives these rats this drug from Ibogaine,

they stop taking drugs. And I'm sitting in an audience listening to his presentation going, wait a minute, that's that same molecule. The last thing that happened was Howard Lutzoff contacted me because our laboratory was getting so much publicity. He had several patents on Ibogaine. And he wanted to file a new patent for polydrug dependency and use our research on co-abuse of cocaine and alcohol. So he called me. And I said, who are you? What does this drug do? How does it work? What's the mechanism of action? And he said, want to come to Amsterdam and see it? And I said, yeah, I do. Here we are. And so you went to amsterdam and you actually witnessed addicts taking the drug and the next

day being symptom free from withdrawal now i'm a physician and there are physiological things that happen it's not a psychological withdrawal i mean there's psychological dependence and physiological dependence and you see with addiction to for example alcohol alcoholists come in when they get off booze, they start to go on tremors. They have all kinds of symptoms, same thing with heroin and opioids. And, uh, and yet somehow this compound erases all of that, which kind of leads to a whole set of questions about what is it doing? How does it work? And I've even heard people share who've taken the drug that it's like a brain reset around not just addiction, but around their personality, around their mood, around their view on life. And it just seems to

sort of have this really magical set of properties. It seems to go beyond just this one dose that you take to kind of deal with addiction. So how have you kind of explored this sort of Pandora's box of this compound that seems unlike anything else we've ever seen? I mean, because there isn't anything in medicine that works like this. You take this thing and it's just like you have to keep taking it as a normal drug. You don't take a statin once and then your cholesterol is fine forever. So how does this work and what is the theory behind it? And what have you learned in the 30 years of researching this about the mechanisms of action? Because if this is true, then it seems to

be such a powerful lever for addressing the opioid addiction problem, but also other kinds of addiction. We've talked about this offline about, for example, food addiction, which we know is a real phenomenon that has to do with the way the sugar affects the nucleus accumbens, the area of the brain that's responsible for pleasure and addiction. So kind of unpack the biology of this compound and what you've learned. Yes, that's a, thank you, doctor. That's a big, obviously a big, big, big question. And I'm quite humble in what we've learned about this drug. But suffice it to say, I was a skeptic walking in the door. And when I saw people were able to come off of 100 milligrams of methadone, young man, 100 milligrams of methadone young man a hundred milligrams of methadone chipping on heroin doing some benzodiazepines you know some xanax on the side a little bit of cocaine for

extra recreation on top of the methadone and completely be detoxified get up the next day no withdrawal shower and shave come, sit down and eat a big breakfast. Because as you know, people who are coming off opiates, they don't have an appetite, they're very sick. So all of the, you know, just complete blockade of all of the classic opioid withdrawal symptoms that are black and white. Here I was in there seeing and believing. And the place in Amsterdam that I visited was not a, what you would expect to see in an academic medical center to say, to be polite. So it was, you know, just people in different rooms in the wing of a hotel that had been taken over, who were going through detox after given one dose. And I thought, this is, you know, wow,

this is really scary here. And I had brought a medical doctor, a colleague of mine from the University of Miami, Juan Sanchez Ramos. And I had Dr. Ramos there, but everybody went to bed. Everybody went to bed. I stayed up all night. So I went from bedroom to bedroom, to hotel room, to hotel room with three gentlemen, two were coming off of opioids and one was coming off. One had been abusing a lot of free-based cocaine. And I went from room to room, sat by their bed, watched them, gave them water. I couldn't really do anything. There weren't any nurses or anything there, but I had an idea. I said, there's no way that you can take one dose of Ibogaine and have this complete reset, to use the word you used, which indeed it is a reset, and all the blockaded withdrawals and people get up and look like they've been

transformed into a new person. There's got to be something going on here. I'm going to collect urine. So I collected urine and I asked them to sign a release for me to collect urine and I froze back urine, brought the box of urine, put it on the plane at the airport, got it on the plane, got it back to Miami, got the box, drove it over to my analytical talks group and gave it to the boys at the bench and said, find the metabolite. And that was how we discovered noribigaine because I was convinced that there had to be an active metabolite, that There was no way that one dose of this drug, albeit it was a large dose, could have this protracted effects on the brain and behavior. I just couldn't understand it.

Yeah, yeah. So we discovered noribigaine. And what we know today is that ibogaine goes through the liver, gets converted to this active metabolite, and the metabolite has a much longer half-life in the blood. So ibogaine is not only an active molecule. So the aneuric effects, the dreamlike visions of ibogaine. Microlucidetic effects. Yeah. The psychedelic medicine effects, if you will, are short-lived. So those are very intense anywhere from about four to eight hours, depending on your liver metabolism,

whether you're a fast, intermediate, or slow metabolizer. And then the ibogaine is cleared from the blood. So the Ibogaine is cleared from the blood in 24 hours. You've cleared the Ibogaine. The Nor-Ibogaine is elevated. So in the days out, you still can measure Nor-Ibogaine in the blood. Half-life here is anywhere from 24 to 27 to 30 hours. So that week, you're tailing off the norivigain. So I became very interested in norivigain. And I thought, well, and we also knew that you could sort of dissociate the oneuric effects. That means hallucinogenic effects. Hallucinogenic effects of the drug. And the reason I use the Oneuric is that what the patients tell us is that it's like a waking dream.

So it's that lucid dream state. People wake up from a lucid dream and, you know, you're in the dream. You're conscious that you're in the dream state, but you're experiencing the dream state. So that is the experience. It's very different than what the patients tell us. It's extremely different than LSD or mushrooms or ayahuasca, for example, or MDMA, completely different. And then when those abrupt, when that visionary experience, hallucinations, the active waking dream state shuts off is when the norivigin peaks in the blood. So what I think today is, and for many people, that experience, the life review.

The patient's job was like, it was like doing a fourth step. I relived a lot of the bad things I did on drugs, how it wrecked my family, how it wrecked me, my career, et cetera. There's this insight that's gained from having that experience. And the therapists who were with us in the Caribbean working with the patients said, you know, Dr. Mash, this is extremely important for them. This is part of the therapeutic benefit of the drug. So I think that the Ibogaine, nor Ibogaine, is like a one-two punch. Ibogaine begins the brain reset. It has effects like other psychedelic medicines on neuroplasticity and synaptic turnover and healing of the brain.

So it starts the reset. It's a little bit ketamine-like. Ibogaine is a little bit like ketamine. It's acting on glutamate systems in the brain, similar to ketamine, but it also has a serotonergic overlay. And then the noribogaine is a very interesting molecule because it has effects on serotonin reuptake also. So the mood, the anti-craving, and the opioid reset is likely mediated by the reaction of opioid, we'll focus on opioids, opioid withdrawal, the acute phase, depending on the opioids that you're abusing, can be, you know, 1 to 2, 36 to 48 to 72 hours of severe withdrawals. Withdrawal, right. The Ibogaine is starting that blockade and mitigating those symptoms. But then what patients really struggle with, they get past the acute. You know, you can take a Clonidine or Lefexidine. You can do a methadone taper.

The Lefexidine and methadone taper are what the FDA has approved for withdrawal management. There are other meds, as you well know, that are used off-label. Off-label, yeah. Yes. So bupren you well know, that are used off-label for treatment. Yes. So buprenorphine taper, for example, off-label. But what patients then struggle with is they feel horrible. They're in a deep, dark, black depression, an anhedonia, a protracted depression that doesn't go away. And over days to weeks in early recovery, you know, you get, you get stressed back in your life. You're not feeling

good. You can't get out of bed. You have no energy and you're, you're just, you're, you were crawling out of your skin. So that contracted state is what fuels the relapse. So for us, the idea of having the Ibogaine, allowing people to have the journey, have this profound experience with the Ibogaine, have the reset, use that as an adjuvant to psychotherapy, use that for behavioral change, as you described well. Use that Ibogaine initiation to be in your group, in your therapeutic setting. And then, much like MDMA is used for PTSD, and you'll know this,

people abuse drugs. Why? Because they're self-medicating. They're medicating anxiety, intractable depression, trauma, all the bad boogeymen that take us offline as human beings and deprive us from self-actualization and the fullness of life. And so if we can allow patients to have that experience, to regain their self-control and to find their locus of control and feel good and feel good, and then follow the Ibogaine detoxification with Noribogaine and a pill, Patcher and Depot in low-dose formulations. We believe we have. Hey everyone, it's Dr. Mark. One of the most important tools I have for helping my patients optimize their health is testing. And that is why I love what Rupa Health is doing. Functional medicine testing can require placing orders with lots of different labs and it can kind of get

really complicated for doctors and their patients to easily access results and keep track of everything. But Rupa Health has totally streamlined that process. Looking at hormones, organic acids, nutrient levels, inflammatory factors, gut bacteria, and so many other internal variables can help us find the most effective path to health and healing. I'm really excited about that now and I can finally take advantage of these tests without the hassle of the confusion of going through so many multiple labs. Rupa Health is the place for functional medicine practitioners to access more than 2,000 specialty lab tests from over 20 labs like Dutch, Vibrant America, Genova, Great Plains, and more. It's 90% faster, letting you simplify the process of getting you the functional tests that you need and giving you more time to

focus on your patients. This is really a much needed option in the functional medicine space and it means better service for you and your patients. You can check it out with a free live demo with a Q&A or create an account at rupahealth.com. That's R-U-P-A health.com. Now let's get back to this week's episode of The Doctor's Pharmacy. That's amazing. So how much of the sort of reset is the process of recovery? In other words, you know, could you just give norabigaine as a pill, which may have less side effects, better tolerated, easier to administer, less complicated, less expensive, and is that good enough?

Or do you think we actually need the full hallucinogenic journey to reset our relationship to reality, self, life, and so forth? That's a fundamental question to be explored. In order to do that, we would have to, as you well know, randomize two groups of subjects and really look at relapse prevention in both groups and see where we are. When I originally was working on Ibogaine, I wanted to focus solely on the metabolite because as you describe it, it will be used as a classic pharmaceutical. It would be easier for patients and practitioners can prescribe it and we can learn about safety and demonstrate dose and safety effects. It may be sufficient. It may be what is needed here to allow people who have been detoxed to transition.

But what we know today is that if you look at depression as a model if we if we take depression as a model you know look at college students today you know i'm always amazed with the numbers of young people that are starting our universities and coming in on antidepressants. Yes, for sure. The numbers are staggering, right? And do we need that? Or is what people are doing, the elegant studies that are being done by Compass and others with psilocybin as a rapid acting antidepressant and as a therapeutic adjuvant for people who are having difficulty with anxiety disorders, you know, other depression, depressed mood symptoms. You know, in the old

days when I went, I remember when I went to college, I probably was depressed. I think my dad died and I was definitely depressed for a while. I had reactive depression. I had anxiety, I had fear, but what did we do? We knuckled up. You know, just get over it, you know. And, you know, I used mindfulness practices. And back then it wasn't called that, but I did yoga and whatnot. And I just focused down. Today, everybody wants a quick fix. And so I think that this is, I'm enthusiastic as a neuroscientist today with the development of psychedelic medicines because I do think that they bring about rapid effects.

We don't know the longevity of these effects. We don't know psilocybin, is it 90 days or longer? And in some subjects it may be. Some subjects maybe need one or two doses to have protracted efficacy and behavioral change. With the Ibogaine, you know, breaking the intractable cycle of addiction to anything, whether it's opioids or whatever, is hard to do. People fall back into the hole. You know, it's hard to do. People fall back into the hole. You know, it's a behavior. So would Ibogaine and the oneric effects help rewire the brain?

And this is Mercinic and others, you know, neurons that wire together. Fire together. Yes. Thank you, doctor. And so, you know, that now I'm, I'm sitting back and, and, you know, kind of reopening my own view of this and thinking, you know what, maybe these molecules are so important at a time when society is more difficult, when people are feeling more isolated, things are too fast, we don't get off the grid enough to allow the brain to heal.

You know, I talk about orthodox, I used to give a neurobiology lecture to elderly folks, and I say, you know, the thing about orthodox Judaism is that people got off the grid. You shut down. Sabbath. Correct. You shut down for one day, spent time with family and your, you know, your belief system, you know, in a quiet spiritual setting. How good for the brain is that?

Think how smart that is. Really. We don't do it. We're constantly, every minute, on the internet, on our phones. You know, it's too much. The nervous system has sensory overload. We need, maybe these molecules have a place because, precisely, they allow this neuroplasticity to give us a window of plasticity. And this idea of cycloplastogen, the term coined by David Olson and the group at Delix Pharmaceutical, who are advancing non-hallucinogenic congeners of ibogaine that could be used pharmaceutically. The idea here is can we, can they, can others make analogs of psilocybin, ibogaine, MDMA, et cetera, that don't bring about the psychedelic journey experience, but turn on this window of plasticity in the brain. And so

this is a really an exciting time because we're learning fun. We're learning something very fundamental about the brain and brain has always been my, you know, that that's my, my muse. I love studying the brain. I've, we've, we neuroscientists have learned more about the human brain in the last 20 years than throughout all of human history, but the answers can't be asked. Yeah. It's pretty, it's pretty extraordinary to see the sort of intersectionality of both the sort of acute psychedelic kind of mystical aspects and antidepressant effect and maybe some other pleiotropic effects we haven't even discovered that make this sort of a long-term maintenance compound for helping maintain people free of addiction. I mean, is that how you're seeing it? It is. That's exactly how we see it. And, you know, really when we were back working in St. Kitts, when I left the United States, we had gotten FDA permission to test Ibogaine in the

90s, 1993 and 1995. The FDA gave us the full green light to bring Ibogaine forward. My issue was I couldn't fund it. I couldn't get NIH funding, even though I've been an NIH funded investigator my whole life. I could not get, you know, buy in. It was it was too early. There were funding these types of studies. And, you know, it was just say no to drugs. And you're going to treat. Can you imagine going up in front of the Congress, the head of the National Institute on Drug Abuse going, doctor, are you funding treating people who are addicted to hardcore drugs with a schedule one hallucinogenic drug? Yeah, right. No, Congressman, Senator, no, we're not doing that.

So, I mean, I understand it. You know, I get it. But at the time, I was so depressed myself that we were the FDA was so collaborative with us and the FDA everybody says why doesn't the FDA fund your studies Dr. Mash no the FDA does not fund research they guide research in drug development but they do not pay for drug development so my issue was getting the money and we didn't have the intellectual property around I began Howard Lutz off at it. So we, you know, this, I was the odd person out here, but when I went to say KITS and the university of Miami was, you know, again, very collaborative and always very good to me as an investigator, gave me the roadmap really allowed me to, to do this, to go, you know,

we didn't have people running a lot of trials now today with, you know, with stem cells and everything, everybody's off into the Caribbean and elsewhere testing in humans. Many of my colleagues are doing that, but back when I did it, nobody was doing it. And so we really had the first government approved psychedelic clinic working with clinicians in St. Kitts, and that's where our safety and open label efficacy database came from. So I was able to bring those data back to my colleagues and peers, and I always had an open door policy. So I invited clinicians, more doctors, the better, who come in there and see what we

were seeing, bring that message back out. But even today, people don't know about Ibogaine. Yeah, it's pretty much under the radar for most people. This whole idea of sort of traditional recovery medicine and rehab medicine and the success rate of that compared to what you're seeing as the success rates with Ibogaine and even Noribigaine treatment. Can you kind of talk about that? Because, you know, even best treatments like AA, you're talking

about 10%, 20% best, like preventing relapse. It's pretty dismal. I mean, so how does this compare to that? It is dismal. That is the word. And of course, and families have lost retirement accounts. Families to save their loved ones have mortgaged, put mortgages up on their houses to pay for rehabs. Which doesn't really work that much. And it breaks my heart. I mean, I speak to families all the time calling me desperate for help. And it really breaks my heart because, you know, here we are and our work can't go fast enough. I can't tell you as I sit here today that what the number is. I will never oversell my science, you know. We don't know because you have to do this in a so-called blinded fashion. And it's going to be hard to blind Ibogaine against the standard of care, as you know. But what we do know is that many of our patients who detoxified with Ibogaine in the Caribbean,

our counselors who were there, worked on an aftercare plan. You know, what's going to be different this time? You just detoxified, but we didn't want people to think that this was a silver bullet because there is no silver bullet. There is no cure for addiction. Addiction is a chronic relapsing disorder. So what's going to be different this time? What's going to be different this time? What's going to be different this time? So we sent our people back into various programs. So the outpatient, some went to inpatient, some, you know, went to meetings, you know, 90 and 90, 90 meetings in 90 days. A lot of our people said, Dr. Mesh, I'm never going to meetings. I forget it. I've done that.

I'm not doing that. I'm never going to meetings. I forget it. I've done that. We're not, I'm not doing that. I'm not going to any of those meetings. And then they would take the Ibogaine and then they come back and they go, I got to go to meetings. So you would see that, you know, that the cognition, what should we call it? Cognition enhancement, like, man, I gotta, you know, I gotta work this thing. I've got to work it. So the clinicians i remember doug talbot who ran a large treatment you know he's an icon in the addiction in the addiction field and he called me he called me with his therapist because we put a few a few people into talbot and he called me he said patients who are treated with ibogaine look like they're 90 days clean. Wow.

He said they're sitting in meetings, they're engaged, they're active, they're planning. They're planning. They're making a plan. And this was just so exciting for us because we were like, wow. So we think that if you just, you know, and again, the FDA is going to give us guidance on what they want to see to get the relapse indication in the label. Yes. Okay. Black and white on the detoxification. But what the big effect is going to be exactly what you're saying, relapse prevention. Can we, is this ritual? Do you think it's like going to be twice as you're saying, relapse prevention. Can we, is this ritual?

Do you think it's like going to be twice as effective, 10 times as effective? I mean, what's it look like? I'm a gambling lady. So I would bet that the numbers are going to be really stunning, that we're going to see an effect size that's very large. And I think others believe that too. I'm not alone here on this.

Because, you know, it's simply, you can deal with the addiction part and the biological piece, but you know, what often drives addiction and we've had Gabbar Mati on the podcast and others is, is the underlying trauma, the, the trauma, whether they're big traumas or little traumas, whether it's abuse or neglect that happened in people's childhood that drives these behaviors when they're older. And so often, like you said earlier, people are self-medicating. And if that's true, then this really opens the door to start to heal those damaged circuits in our brain. But it's not the only piece of the solution.

No, it's not. So the therapy and the post of post work, if you will, around the treatment of addiction after Ibogaine and or Ibogaine, what does that look like? And how is that different? And how do we kind of reimagine it? Because, you know, in traditional AA, there's not a lot of talk about trauma. There's not a lot of talk about these underlying reasons. It's just, you're an addict. That's it. Give yourself to a higher power and just fix it all. But it's not really dealing with the meaning you made of what happened to you and the trauma that happened to you when you were younger that drove these addictive behaviors.

I think pharmaceutical industry has shied away from developing medications for the treatment of addiction precisely because there's so much comorbidity in this cohort. These patients find their way to drugs and alcohol, maladaptive behaviors for a variety of reasons. So it's not a one fit for anybody. And if you look at the epidemiology, I mean, straight away, you know that women don't get addicted. We're somehow protected biologically. Maybe we walk around with more dopamine because of estrogen. I think we do, actually. I think our- Women don't get addicted? Yeah, no, they're less likely to get addicted. However, when women become addicts, oh, my goodness, they are sicker than men.

So the comorbidity, I worked with a brilliant psychiatrist who was our clinical director, Dr. Frank Herbin, trained my mentor at Harvard. And Harvard psychiatrist, UCLA, McGill university. So when I started St. Kitts, we needed to clinically phenotype our people. And I went to Frank, I had been doing research in St. Kitts with alcohol drinking monkeys down there. That's a whole nother chapter. Dr. Urban, biological psychiatrist, skeptic, you know, he, he died a few years ago, and I miss him so very, very much. But anyway, Dr. Dr. Urban, you know, the first round of patients who went through

St. Kitts, he came to me, his glasses went down on his nose, and he looked at me and he said, well, Deborah, it blocks opioid withdrawals. And then I had Dr. Irvin engaged in this. And so we spent a lot of time actually doing all the classic psych assessments to understand who was there. And what we learned in our cohort was that in the opioid-dependent group, about 50% of them were major depressive disorder, five of them. So I think opiates, a lot of people will find their way to opiates. Maybe, you know, start using them recreationally, as you pointed out, legitimate pain patients who continue to take opiates. You know, somebody like me, I hate opiates. Opiates for me are dysphoric. I go in, if I have a minor surgical procedure and I get prescribed opiates, I don't take them. I don't like them.

They feel horrible. I feel horrible. I don't like them. I don't need them. Other people, you know, you can imagine the mommy who's cesarean section the doctor gives post c section gives an opiate and you know 90 days later she's still asking for opiates yeah that's our girl you know she's now escalated so she's probably you know medicating self-medicating something else going on there depression i think, is primary for opiates. For cocaine, we had a lot of comorbidity. We saw comorbidity with attention deficit disorder. You're not surprised by that. Also, bipolar disorder. You're not surprised by that. And the third group was family history positive for alcohol. So, you know, cocaine and alcohol go together this was my epithelium research yeah so there's what i'm trying to say is there's an underlying neurochemical setting that's going on in the brain

and people are attracted to different classes of substances be it alcohol cocaine and or nicotine, or opiates, that you can kind of separate them out. And so you've got to understand what's the underlying thing. In terms of the work, the seminal work of Gabor Mate and others, you know, yeah, there's a lot of trauma. Yeah. A lot of sexual abuse. And women, we saw that. And men too. Men too. Childhood sexual abuse and women uh we saw that and men too men too childhood sexual abuse amazing stunning crazy crazy when and i was away from the therapeutic group i stayed away from that

i allowed the clinicians i'm not one oncologist clinicians work with patients. But when I went in on a research way and started to read charts, I couldn't believe what I was reading there. So that's a huge driver of maladaptive behaviors. We know this. We know this. I mean, I think for sure all the trauma plays a role. And I think so dealing with that in the post sort of treatment, acute treatment with Ibogaine or any other sort of addiction disruptor seems really important. And so the therapy associated with it. And I was just talking to a guy named Jeff George, who's the chairman of MAPS, the Multidisciplinary Association for Psychedelic Studies.

He was talking about the goal they have of getting FDA approval for MDMA-assisted therapy. So it's not just the drug itself, but it's combined with a whole therapeutic approach that allows you to deal with the underlying issues that caused the problem in the first place. So it seems like it's not an either-or, but it's a both-and. I think that's right. And the other idea that I have in the back of my mind is, you know, when people would first go into rehab, get clean, get sober and go into rehab, there wasn't a lot of time or energy to work on trauma. The only thing you could work on was how am I going to not go out and get high? Yeah. So I can see a world where you can use IBA as an addiction interrupter and then get down

to what's underneath there. What is the clinical phenotype? What are the underlying issues? Is it intractable depression and you're self-medicating that? Okay, well, now you've just taken Ibogaine, you're washing out your nor-Ibogaine, and maybe your depression will start to come back. And maybe over weeks to months, you're going to start to feel, you know, a wearing off effect of the item. Now, would you be a good candidate, perhaps, for ketamine series? Maybe. How about you're a good match to psilocybin therapy? Maybe you are. So what is driving? Is it a dopamine mediatedated depression or is it a serotonergic mediated depression and here's where the biomarkers are going to come in and the clinical phenotyping

to allow us to better understand you know what's driving the disease of addiction what's driving the disease of addiction same thing with trauma. You're now got detoxified people. They're not craving drugs or alcohol. Can you then have them work with the MAPS protocol to start to heal the underlying traumas and move people out of that state. So that's why I'm so excited. And the young generation, the next generation of psychiatrists and therapists will have these tools. How wonderful is that? My father died, I will share with your listeners, my father died at 56.

Alcohol used his sword. He was brilliant. He was funny, brilliant, spiritual, well-read man, self-taught in many ways, but he had a horrible trauma in his life. And he experienced a major PTSD event and the loss of the life of his brother. In some ways, he blamed himself. I think he did. I was, I was a child, so I didn't really know what was going on with my father's mental health,

but he, he white knuckled sobriety. He did everything he could to not drink. I mean, he fought it, but stress and whatnot would get him. But when he drank alcohol, it was not a good,

it was not good. And it ultimately worsened his myocardium, his heart, and he died. He died of a broken heart, but he died. He broke his heart completely. And so I saw him suffer, and he's a great motivation for me to keep working on this, yes? So true. Let me ask you about something that you talk about, which i think is a really interesting concept called psychoplastogens which turn on increased connections in the brain enhanced neuroplasticity called synaptic plasticity which means the ability

of the brain to make new connections to learn to change to grow, to repair. Can you talk more about this? Because it seems to be that many of these compounds that come from nature, whether it's psilocybin or 5-MeO, the toad, or whether it's ayahuasca or peyote or San Pedro cactus or ibogaine from the iboga tree, they all seem to have this kind of property. Can you talk more about it, what we know about it, what it means, what the implications are for medicine? This, to me, is one of the most exciting areas of this.

Maybe it is the most exciting area of psychedelic medicine research going forward because we have more neurons and neural connections in our brain than there are stars in the Milky Way galaxy. Think about that. And they turn over. They turn over. You have, you know, we're constantly building and remodeling the brain. And I'm the former director and founder of the University of Miami Brain Endowment Bank,

one of the largest post-mortem collections of human brains that anybody had in the world. And I went around asking people to please donate their brain for medical research. So we had, actually, I did a lot of my research was, as I mentioned, in the field of Alzheimer's disease and from a nerdy, you know, neurodegenerative disorders, and then moved into neuropsychiatry. So I actually looked at how drugs and alcohol affected the brain. And we know that it hijacks the DNA, it turns on a lot of second messenger systems. It remodels the brain. There's actual remodeling of the brain.

You're overwiring certain circuits in the brain that are part of this intractable cycle of misuse of drugs or alcohol. That's what happens. And so here now. On the negative sense, the, these toxic compounds actually damage the brain and create disconnection, whereas these other plant compounds create reconnection. Yes. So they help heal the brain.

And, and, and that's just, to me is so incredibly exciting. The other thing is that most of the classical psychedelics turn on serotonin growth factors, or what we call brain-derived growth factor, EDNF, neurotrophic factor. And Ibogaine is unique in its box because it turns on dopamine growth factors, allele-derived neurotrophic factor. so that makes perfectly good sense because we know that all roads everything that people will abuse they're abusing it to get the dopamine buzz so if you're low dopamine and you go out and you have that first vodka martini that cigarette that line of cocaine that that smoke a little heroin, chase the dragon, you're going to get this huge dopamine.

So if you're low dopamine, and then you take a drug which gets you high, it gets you high because it turns on dopamine. What if Ibogaine is turning on the plasticity modulator, GDNF, to help normalize dopamine in the synapse. And this is seminal research that was advanced out of the Gallo Institute by a scientist by the name of Dorit Rahn, and her group did some of the original work on this. This is very, very exciting because,

again, these molecules are turning on synaptic blastocystin. Yeah, this is huge. So what you're saying just in English for people listening is that sort of typical psychedelics increase serotonin by activating various growth factors that increase serotonin in the brain and the function of serotonin, the receptors and so forth. And that can help with depression and mood and many things we see with the traditional psychedelics like mushrooms or psilocybin, MDMA and so forth. What you're saying with Ibogaine and Iboga is that it actually affects the dopamine system,

which is what we need to focus, pay attention, be alert, what we want to stimulate for pleasure. It's really the pleasure place in the brain drive motivation and affect or what i like to say drug sex and rock and roll exactly why we get why we have coffee in the morning is it increases adrenaline dopamine right so that's amazing it just occurs to me that maybe you know that has wider applications because you take disease like parkinson's disease that are dopamine deficiency problems. Could this be effective in Parkinson's or other uses besides just addiction medicine? Well, people have tried to bump GDNF, glial-derived neurotrophic factor, in the brain for treatment

of Parkinson's disease. You know, it's very hard to give exogenous growth factors and get them into the brain. So the fact that these psychedelic molecules turn these things on is just crazy good. It's just wonderful science. So I have a question I'm asking, which you may not have an answer to, which is always on the top of my mind which is how does it know right now how do these plants know what to do with our biology in other words how do how do the compounds in these plants bind to certain receptors activate different pathways it doesn't seem to make sense because we're humans they're plants what do they have to do with one another how does it work what did we did we evolve with these compounds to help regulate our biology? I talk a lot about food as medicine, and I do see

that these compounds are not nice to have. They kind of have to have compounds if we want to stay healthy, whether it's the anti-inflammatories in food, the antioxidants in food, the phytochemicals that help regulate all our longevity switches. And I just finished writing a book on longevity and it's just fascinating to look at these phytochemicals and how our bodies use these compounds from plants, not just for psychological purposes, but for maintaining all of our biological systems from mitochondria to our microbiome, to our immune system, to our detoxification systems, our hormonal regulation All of this is controlled in part by these plant compounds. So what's your kind of thinking about how this works? Because these compounds have been used in cultures for thousands of years. Somehow we figured it out. And humans have been using this

as their spiritual doorways in cultures for thousands of years. And suddenly we're sort of figuring out that they have these other properties that may be medically useful. So how does that work? How does it know? Plant teachers, right? Plant teachers. I started the discussion with you about alkaloids, that Mother Nature gives us addicting alkaloids,

and Ibogaine is Mother Nature's antidote to addiction, right? So it makes sense to me. They, we definitely throughout human evolution, our brains changed and our liver and our cytochromes that detoxify things that we eat evolved and adapted. There's no doubt about it. So there is this effect on the neurochemistry

and signaling pathways in our brain that have evolved over the course of human evolution. There's no doubt about it. As our brain expanded and we developed language evolved over the course of human evolution. There's no doubt about it. As our brain expanded and we developed language and all these things and the written word that the food and our environment and the things we're exposed to in the environment, whether teas or tinctures or plant medicines that were known and lost to us. Yeah.

Had real effects and beneficial effects. So, you know, I look at this with an open mind and recognize, and I too, I'm a true believer in food is medicine there's no doubt i mean there's no doubt about this you feel better when you eat right hello and the science is there to back it up which is quite amazing yeah you know it's a it's sort of funny i think about um the sort of anthropocentric hubris you you know, our, our conceit as humans that we're separate from the natural world, that we're independent from it, that we don't really need it, that we can live in these concrete boxes and cities. And the truth is that we, you know, we can eat astronaut food and be fine and live on Mars and be disconnected from the world.

We are biological organisms, whether we like it or not, we're part of nature and, and we are intimately connected with nature in these incredible ways that are so mysterious to me, you know, and I think, um, Einstein said it really well. He said, I'm not interested in the spectrum of this or that element. I'm interested in the thoughts of God, the rest are details. So what are the thoughts of God? What is the mind of God? And this is sort of what we're talking about is how does, how does this sort of the orchestration of these molecules and our molecules all work together to create

healing repair rejuvenation the end of suffering i mean it's just it's kind of like an existential sort of uh uh you know kind of um festival to think about all these things where we get to you know it's i'm going to use that i think you think, you know, I'm kind of an overachiever and lived my life full catastrophic for a lot of years and tried to control everything and, you know, adult child of an alcoholic. So I fit that, I kind of fit that mold. But I woke up one day and, you know, had the epiphany in my own head, which was, you know, all knowledge exists in the mind of God, and you don't own this, Deborah, so relax. Exactly.

You know, and I think this renaissance, this existential festival of knowledge that couldn't come at a more important time for us as part of the human family. And we really need to learn from the great religions and from the ethnobotanical and plant teachers and wisdom. We need to call in this wisdom. It's really true. I was once in the jungle in Peru Peru and I met this guy who was an ayahuasca who was administering ayahuasca. And for those who don't know, it's a combination of

plants, any one of which might kill you if you took it alone, but together they seem to have this beneficial effect. I said, how did you figure this out? Did a bunch of people die? He says, no, no, the plants told us. I'm like, what, you talked to the plants? He's like, yeah, the plants told us. And I'm like, it's just a realm of knowing and knowledge that we don't really accept or are familiar with in the West, but it really is what these ancient cultures have done. I always wondered how we sort of survived all these years, because there's so much nasty stuff around. If we eat, we're going to die. So how do humans even survive? But somehow we figured it out. I want to sort of pivot a little bit to talk about people who might be listening and wondering about getting treatment. One of the challenges

that I've come to understand around Ibogaine, it's not like psilocybin or LSD where there's very little lethality. These are very safe compounds at very high doses. There'll be something called LD50 in medicine, which is a lethal dose, you know, 50. That seems to be not so much of an issue with these other compounds, but with Ibogaine and Iboga, it seems to be tricky and that there's a real cardiac risk in these compounds and administered in therapeutic settings like in Costa Rica or Mexico where they're used in clinics for addiction. You know, they hook people up to an IV, they put them on an echocardiogram, they give them oxygen, they watch them, there's medical supervision. Can you talk about this sort of aspect of it and how we navigate it and how dangerous is it and is the nor-ibigaine also risky or is it just the regular Ibogaine at hallucinogenic doses? Ibogaine

has been administered to desperate people in unsafe settings and there have been deaths. And your listeners need to know this and understand this. And something that I've spoken about with a very loud voice, and some people get angry with me about this, but the facts are the facts. Nobody who wants to have a chance to break out of the pattern of maladaptive use of drugs or alcohol deserves to be given Ibogaine by someone who doesn't know what they're doing.

There are unfortunately unethical individuals and it really is a buy or beware kind of situation. And people buy Ibogaine on the internet. They send, families will send emails and say, Dr. Bash, I've just bought some Ibogaine on the internet. And I'm like, oh, hell no. No, you did not. And do not give that to your child or your son or your daughter or your husband. No, no, you can't do that. You need to be under medical supervision by a qualified clinician. You need a doctor who knows what he or she is doing, period. End of story. Having said that, when we started Insane

Kids, we had no idea of any of this, okay? we have no idea about what the benefits to risk were for Ibogaine, what the therapeutic free plasma, the safe plasma concentration was in humans. And Howard Lutzoff had been giving gram quantities of Ibogaine, which is ridiculous. I mean, that's a lot of Ibogaine. And so people look back at some of those early publications and think, well, I can take that. No, you can't. No, you cannot. You should not. And you don't. So what we did in St. Kitts, and I even think about it now, I look back on, you know, my, our database and our results. We, we treated um our clinicians our doctors there uh administered ibogaine to 277 people most were opiate dependent but there were also cocaine some were out by alcohol or poly

drug dependent and we did not have any deaths in St. Jude's. But everybody was hooked up to where they're on telemetry the whole time. We prepared them to take the Ibogaine. We did full medical evaluations. Some had, everybody had an EKG before they went in. And some people had halter monitors or other cardiac testing to ensure that they were cardiovascularly fit to take Ibogaine because Ibogaine does have an off-target effect on the heart, just like methadone. Methadone causes what we know to be QT prolongation. So the refractory period of the heart changes. And that's a dangerous thing to happen. You don't want that. Because when that refractory period changes, if there's any disease in the heart, then you have the risk of having a lethal arrhythmia. So it's only people with pre-existing heart disease is what you're saying?

We believe that. Also, as you well know, magnesium deficiency. Many people who are using drugs and alcohol, they're not nutritionally fit.'re so you got to do their labs but even when you do their labs and you measure these things you don't know what their magnesium and calcium stores are in the heart so you need to get people ready for ibogaine you need them to be ready and you need to have the medic you know a good medical clearance and you have to have clinicians doctors who doctors who know how to run to manage an event in the event that you see an adverse effect of the drug. And those are manageable if they have them. They are manageable, doctor.

They are manageable if they have them. So you're saying in a well-supervised clinic that's run by physicians who are knowledgeable about how to manage these events, that it's a very safe treatment. That is that. I have written that. We've published on that. I have lectured on this, and I've spoken about it. And today, as we're running our clinical trial, we are currently doing that safety. Right now, that's what we're focused on is defining the safety window. So as

you said, psilocybin is extremely safe. It's hard to get in trouble with psilocybin, right? It's a huge therapeutic to toxic window, huge. For Ibogaine, it's more more narrow so we need to define it we need to define it and we need to know that's the that's the concern with ibogaine yeah so so you're doing the hero's work which is actually the drug research the hard clinical trials proving the safety the the efficacy, the dosing, trying to get it approved by the FDA so it can be widely adopted. But that could take years still. It's an arduous, slow process. And now there's more funding for this research. There's more interest in it. You've been doing this for decades in the dark wilderness, but now the light is coming. That's good news for everybody. And yet still we're facing this,

you know, juggernaut of addiction, not just opiate addiction, but all sorts of addiction, alcoholism, food addiction, work addiction, gambling addiction, cocaine. I mean, just all the substances, nicotine. It seems as though people hearing this might be, well, thinking, well, I don't want to wait. I know there's clinics in Mexico or Costa Rica or who knows where. Should I go? And should I do it? And what would you say to them? I'm sure you've been asked this question and probably as a scientist, you can't really advise that they do it, but it just seems like a desperate situation where we have a cure or a treatment, but it's not approved and yet

it works. That's an important, that is an important question. And you raise an important concern for people who are desperate, have loved ones and want to know where do I send a loved one to get Ibogaine? And I will tell you, I will share that one of my family members, I had to send for an Ibogaine treatment. And I send them to a place in Mexico with a doctor who trained with us in St. Kitts. When I had a loved one, we didn't have a clinic anymore in St. Kitts. And here was someone in my family, family member who needed a detoxification. And I got that phone call and said, you have to detox this person in our family. And I was like, what? So I picked up the phone and I knew where to go.

And I called someone and the doctor was wonderful and they took care of my loved one. She had a safe, by the game, treatment. And she's doing very well, and she has a child coming in. I'm very excited about all of this stuff. It's difficult. Families need to ask the question. I haven't gone down and vetted all these different places. There are Ibogaine clinics popping up everywhere. Speak to your doctor.

Speak to the doctor who's going to be there. Make sure that you get the right cardiac tests. Speak to your clinician in the US. Tell him or her what you're thinking about doing. Get the information. Read. Read online. People can send me emails. They do, or they find me, they call me all the time, and I'll discuss it with you. I feel that that's a responsibility that we have. I think there are some places that are it with you. I feel that that's a responsibility that we have. I think there are some places that are better than others. I won't endorse any of them on this call right now, but please, please, please ask the right questions and make sure that you know

that what is being administered is in fact Ibogaine, because I think people take stuff that they're not sure even what it is, and make sure that you're with a clinician. Make sure you have a doctor who's working with you. Well, I appreciate that. And I think people will be interested to sort of hear that this is a treatment available and maybe it's worth exploring. You know, I know you can't answer this because you don't have a crystal ball, but given you're so deep in the weeds on the research and the FDA approval process, what's your best guess and where we're going to end up with a FDA approved treatment that includes noribigaine or ibogaine? I think about this every day as I wake up with this thought in my mind. I know you do.

It's all consuming for me. A little bit going to be the luck of the draw, right? So right now we're doing the dose escalation safety arm, and I have an assembled stellar world-class cardiologist, electrocardiologist. So, you know, this is the big testing and it's an expensive study and we're doing it and we're going to get the answers that the regulatory agency needs to know. Once we get the answers and we've got exposure response and we know that Ibogaine can be administered safely and what we think we're seeing is a little benign transient QT prolongation. You know, methadone is a QT prolonging drug. I'll just throw that out there for the listeners.

So drugs that cause QT prolongation have been approved by the FDA and other regulatory agencies. They're in use. Doctors know this and they're aware of drug interactions and whatnot. As we discussed, with that information, then we move into what is called a proof of concept study. Now, if, or I'm going to say when, we demonstrate what we've already seen in open label research and published by other groups, separate from the work that I've done with my colleagues, other people who've done the same kinds of things and have publications in peer-reviewed medical journals, when we demonstrate the efficacy endpoint, then we have an opportunity, working again with the FDA and other regulatory agencies, to get what Compass Pharmaceutical has.

Yeah. Breakthrough designation. Yeah. And with that, then the question is going to be the safety database. What's going to be the size of the safety database in phase three? Is it going to be 500 people, 600 people, 1,000 people? What are the regulators going to ask us to see? And I think, given the magnitude of the problem, the trillions and trillions of dollars that are

being spent, the lack of other molecules that are entering the pipeline, that the regulatory agencies will absolutely foster this research. I think that that pharmaceutical company, that Purdue Pharmaceuticals, that was responsible for a lot of the epidemic and who really had to pay billions of dollars in fines, that those billions should go to funding this kind of research. I do too. Like the tobacco companies had to pay money for funding. Absolutely. And I, you know, and I think again,

this, I can't work fast enough. It personally, as a, as a person, I can't work fast enough on this. And I regret that we don't go faster. But we're doing it and we're here now. And with the support of don't go faster, but we're doing it. And we're here now.

And with the support of Atai and the investors at Atai, we have the funds available to do this research, to do it the right way. This is really, as you said, this is a landmark study. It's so exciting what you're doing, Debra. I mean, I think the work you've put in over the last 25 years is clearly paying off. There's going to be millions, if not billions of people that benefit from this directly and indirectly. I think, you know, hopefully you get the Nobel Prize for this. That's my goal.

So you get recognized for this work because it's so important and it's such a pernicious problem. And it is one of the most hopeful podcasts that I've had because it lays out a roadmap for people who are suffering with addiction that has been pathologized. And it's often just a result of trauma and not given really adequate treatments and not given adequate thinking about what causes it or how to deal with it. It's due. And I just, I'm so grateful for you and your work. And I think if people want to learn more, they can certainly learn more at Demerex, D-E-M-E-R-E-X.com. That's the company that's trying to get this licensed and approved. There's clinicaltrials.gov.

You can look at the study protocol that's being used. This is real hardcore science. This is not some crazy fringe thing. And thank you for being dedicated and doing this work for so many decades. Thank you for engaging me in this discussion. And congratulations to you, doctor, and to all your listeners for staying well and staying healthy. Thank you for the good work you do. Thank you. And everybody listening, if you love this podcast, please share with your friends and family on social media. We'd love to hear from you. Maybe share how you struggled and found a way out of addiction, maybe using some of these strategies. Subscribe wherever you get your podcasts and we'll see you next week on The Doctor's Pharmacy. Hey everybody, it's Dr. Hyman. Thanks for tuning into The Doctor's Pharmacy. I hope you're loving

this podcast. It's one of my favorite things to do and introducing you all the experts that I know and I love and that I've learned so much from. And I want to tell you about something else I'm doing, which is called Mark's Picks. It's my weekly newsletter. And in it, I share my favorite stuff from foods to supplements, to gadgets gadgets to tools to enhance your health. It's all the cool stuff that I use and that my team uses to optimize and enhance our health. And I'd love you to sign up for the weekly newsletter. I'll only send it to you once a week on Fridays. Nothing else, I promise. And all you do is go to drhyman.com forward slash pics to sign up. That's drhyman.com forward slash PICS, P-I-C-K-S,

and sign up for the newsletter, and I'll share with you my favorite stuff that I use to enhance my health and get healthier and better and live younger longer. Hi, everyone. I hope you enjoyed this week's episode. Just a reminder that this podcast is for educational purposes only.

This podcast is not a substitute for professional care by a doctor or other qualified medical professional. This podcast is not a substitute for professional care by a doctor or other qualified medical professional. This podcast is provided on the understanding that it does not constitute medical or other professional advice or services. If you're looking for help in your journey, seek out a qualified medical practitioner.

If you're looking for a functional medicine practitioner, you can visit ifm.org and search their Find a Practitioner database. It's important that you have someone in your corner who's trained, who's a licensed healthcare practitioner, and can help you make changes, especially when it comes to your health.